Across TCGA pan-cancer cohorts, SLC39A10 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC39A10 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC39A10 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC39A10 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, HNSC, and GBM are the cancer types where SLC39A10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.253	0.647	<.001	75	view →
HNSC	DFS	Median	IV	0.478	0.811	<.001	27	view →
GBM	DFS	Median	All	0.853	0.651	.010	9	view →
LUAD	DFS	Quartile	All	0.973	0.890	.021	6	view →
LSCC	DFS	Tertile	All	0.537	1.000	.030	2	view →
CCRCC	DFS	Median	II,III,IV	0.391	0.762	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: SLC39A10 tumor-vs-normal RNA expression · all SLC39A10 data types